

BRCA1 (m): 293T Lysate: sc-125063

BACKGROUND

In 1990, a breast cancer susceptibility gene, designated BRCA1, was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-q13, also confers a high incidence of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1,863 amino acids. This protein contains a zinc-finger domain in its amino-terminal region, but is otherwise unrelated to any previously described proteins. Like many other genes involved in familial cancer, BRCA1 appears to encode a tumor suppressor, a protein that acts as a negative regulator of tumor growth.

REFERENCES

1. Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B. and King, M.C. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 250: 1684-1689.
2. Narod, S.A., Feunteun, J., Lynch, H.T., Watson, P., Conway, T., Lynch, J. and Lenoir, G.M. 1991. Familial breast-ovarian cancer locus on chromosome 17q12-q23. *Lancet* 338: 82-83.
3. Novak, R. 1994. Breast cancer gene offers surprises. *Science* 265: 1796-1799.
4. Wooster, R., Neuhausen, S.L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., Fields, P., Marshall, G., Narod, S., Lenoir, G.M., Lynch, H., Feunteun, J., Devilee, P., Cornelisse, C.J., et al. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-q13. *Science* 265: 2088-2090.
5. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., Melody, M., Frye, C., Hattier, T., et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266: 66-71.
6. Futreal, P.A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L.M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., et al. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. *Science* 266: 120-122.
7. Maul, G.G., Jensen, D.E., Ishov, A.M., Herlyn, M. and Rauscher, F.J. 1998. Nuclear redistribution of BRCA1 during viral infection. *Cell Growth Differ.* 9: 743-755.
8. Houvras, Y., Benezra, M., Zhang, H., Manfredi, J.J., Weber, B.L. and Licht, J.D. 2000. BRCA1 physically and functionally interacts with ATF-1. *J. Biol. Chem.* 275: 36230-36237.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: Brca1 (mouse) mapping to 11 D.

PRODUCT

BRCA1 (m): 293T Lysate represents a lysate of mouse BRCA1 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

BRCA1 (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive BRCA1 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.